advertisement
 

  Back to Polls Poll Results
Poll Results
  Which insulins do you or your child use?  
  Vote for all that apply  
  Short acting insulins  
      NovoLog / Novorapid  
  42%     101  
      Humalog  
  18%     43  
      Apidra  
  9%     21  
      Regular / Actrapid / Velosulin  
  1%     3  
      Other short acting insulin  
  0%      0  
  Long acting insulins  
      Lantus  
  21%     50  
      Levemir  
  4%     10  
      NPH / Isophane / Insulatard  
  3%     8  
      Other long acting insulin  
  1%      2  
  Other  
      Premixed (70/30, etc.)  
  1%      2  
      Other insulin  
  0%      0  

Total votes: 240
 

Which insulins do you or your child use?

Poll dates: January 16 - 23, 2013
Total Votes: 140

Insulin users today have a great variety of products from which to choose. Fast-acting analogs (Humalog, NovoLog, and Apidra) and long-acting analogs (Lantus and Levemir) have changed the way many people use insulin. The use of Regular insulin among our readers has dropped off to one percent. NPH use has dropped too, from 32% in 2000 to just 5% today.

This table shows readers' answers to this survey over the past years:

  Answer     Jan 2013     Jan 2012     Jan 2011     Jan 2010     Jan 2009     Jan 2008     Jan 2007     Jan 2006     Jan 2005     Jan 2004     Jan 2003     Jan 2002     Mar 2000  
Short acting insulins
NovoLog 41% 42% 40% 40% 38% 35% 33% 28% 27% 26% 12% 3% --
Humalog 17% 18% 17% 21% 18% 19% 17% 20% 22% 26% 34% 37% 35%
Apidra 9% 9% 5% 4% 5% 1% 1% 1% 1% -- -- -- --
Regular/Other 1% 1% 1% 1% 1% 1% 1% 1% 1% 2% 3% 4% 12%
Long acting insulins
Lantus 24% 21% 24% 23% 28% 30% 31% 32% 27% 21% 17% 11% --
Levemir 6% 4% 6% 3% 4% 4% 4% 2% 1% -- -- -- --
NPH 1% 3% 4% 4% 5% 3% 6% 8% 14% 16% 22% 28% 32%
Other 0% 1% 0% 0% -- -- -- -- -- -- -- -- --
Lente -- -- -- -- -- 0% 1% 1% 1% 1% 1% 3% 4%
Ultralente -- -- -- -- -- 1% 1% 1% 1% 1% 2% 5% 7%
Other
Premixed 0% 1% 0% 1% 1% 1% 1% 1% 1% 1% 2% 2% 5%
Other insulin 0% 0% 1% 1% 1% 2% 1% 1% 1% 1% 2% 2% 2%
Percentages based on use compared with all responses

Looking at answers in the short-acting and long-acting insulins shows a dramatic change since 2000. The following graphs illustrate the rapid increase in use of insulin analogs and the concurrent decline in the use of Regular and NPH.

Rapid Acting Insulin Use

The rise in the use of NovoLog has been particularly significant since it was introduced in 2002. Among users of rapid-acting insulin, NovoLog is used by almost two-thirds of our visitors (60%), while one-fourth (25%) use Humalog and 14% use Apidra. The use of Regular continues to decline and is now at just 1%.

Graph
Data within rapid-acting insulin only

Graph
Data for rapid-acting insulin among all responses

Long Acting Insulin Use

As of January 2013, more CWD visitors report using Lantus than any other long acting insulin by a wide margin. This year, 77% of people who use long acting insulin report using Lantus. The use of NPH continues to decline and and now stands at just 5% for people who use long acting insulin. Levemir, new in 2005, is used by 19%. Given the clinical benefits of using Lantus or Levemir over NPH, it's no surprise to see the rapid decline in use of NPH. (See our page about Care Suggestions for citations to studies about NPH.)

Graph
Data for long-acting insulin only

Graph
Data for long-acting insulin among all responses

[Download an Excel spreadsheet with the data and graphs from this poll]

[Return to the current poll]



                 
  Home Return to Top

Last Updated: Wednesday January 22, 2014 21:21:20
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2015. Comments and Feedback.